Hypoxia-driven angiogenesis: Role of tip cells and extracellular matrix scaffolding

Current Opinion in Hematology

Volumn 17, Issue 3, 2010, Pages 245-251

  Germain, Stéphane ^a,b   Monnot, Catherine ^a,b   Muller, Laurent ^a,b   Eichmann, Anne ^a,b  

^a INSERM   (France)

^b l'alimentation et l'Environnement   (France)

Author keywords

Angiogenesis; Extracellular matrix; Hypoxia; Matricellular; Tip cell

Indexed keywords

NOTCH RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; BASEMENT MEMBRANE; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME REGULATION; EXTRACELLULAR MATRIX; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANOXIA; BLOOD VESSELS; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; SIGNAL TRANSDUCTION;

EID: 77951498319     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32833865b9     Document Type: Review

References (82)

1. 2 availability on human cancer. Nat Rev Cancer 2008; 8:967-975.
2. Fraisl P, Mazzone M, Schmidt T, Carmeliet P. Regulation of angiogenesis by oxygen and metabolism. Dev Cell 2009; 16:167-179.
3. Lendahl U, Lee KL, Yang H, Poellinger L Generating specificity and diversity in the transcriptional response to hypoxia. Nat Rev Genet 2009; 10:821-832.
4. Gerhardt H, Golding M, Fruttiger M, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003; 161:1163-1177.
5. Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008; 454:656-660.
6. Strilic B, Kucera T, Eglinger J, et al. The molecular basis of vascular lumen formation in the developing mouse aorta. Dev Cell 2009; 17:505-515.
7. Carmeliet P, De Smet F, Loges S, Mazzone M. Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat Rev Clin Oncol 2009; 6:315-326.
8. Mazzone M, Dettori D, Leite de Oliveira R, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009; 136:839-851.
9. Lee KA, Lynd JD, O'Reilly S, et al. The biphasic role of the hypoxia-inducible factor prolyl-4-hydroxylase, PHD2, in modulating tumor-forming potential. Mol Cancer Res 2008; 6:829-842.
10. Chan DA, Kawahara TL, Sutphin PD, et al. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 2009; 15:527-538.
11. Du R, Lu KV, Petritsch C, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008; 13:206-220.
12. Skuli N, Liu L, Runge A, et al. Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis. Blood 2009; 114:469-477.
13. Takeda N, Maemura K, Imai Y, et al. Endothelial PAS domain protein 1 gene promotes angiogenesis through the transactivation of both vascular endothelial growth factor and its receptor, Flt-1. Circ Res 2004; 95:146-153.
14. Scheurer SB, Raybak JN, Rosli C, et al. Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: a transcriptomic and proteomic study. Proteomics 2004; 4:1737-1760.
15. Ning W, Chu TJ, Li CJ, et al. Genome-wide analysis of the endothelial transcriptome under short-term chronic hypoxia. Physiol Genomics 2004; 18:70-78.
16. Manalo DJ, Rowan A, Lavoie T, et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 2005; 105:659-669.
17. Peters DG, Ning W, Chu TJ, et al. Comparative SAGE analysis of the response to hypoxia in human pulmonary and aortic endothelial cells. Physiol Genomics 2006; 26:99-108.
18. Le Jan S, Le Meur N, Cazes A, et al. Characterization of the expression of the hypoxia-induced genes neuritin, TXNIP and IGFBP3 in cancer. FEBS Lett 2006; 580:3395-3400.
19. Ruhrberg C, Gerhardt H, Golding M, et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 2002; 16:2684-2698.
20. van Hinsbergh VW, Koolwijk P. Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc Res 2008; 78:203-212.
21. Bougatef F, Quemener C, Kellouche S, et al. EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2. Blood 2009; 114:5547-5556.
22. Chappell JC, Taylor SM, Ferrara N, Bautch VL. Local guidance of emerging vessel sprouts requires soluble Flt-1. Dev Cell 2009; 17:377-386.
23. Suchting S, Freitas C, le Noble F, et al. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci USA 2007; 104:3225-3230.
24. Hellstrom M, Phng LK, Hofmann JJ, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007; 445:776-780.
25. Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting nonproductive angiogenesis. Nature 2006; 444:1032-1037.
26. Gustafsson MV, Zheng X, PereiraT, et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 2005; 9:617-628.
27. Phng LK, Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev Cell 2009; 16:196-208.
28. Benedito R, Roca C, Sorensen I, et al. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 2009; 137:1124-1135.
29. Phng LK, Potente M, Leslie JD, et al. Nrarp coordinates endothelial Notch and Wnt signaling to control vessel density in angiogenesis. Dev Cell 2009; 16:70-82.
30. Yamanda S, Ebihara S, Asada M, et al. Role of ephrinB2 in nonproductive angiogenesis induced by Delta-like 4 blockade. Blood 2009; 113:3631-3639.
31. Salvucci O, Maric D, Economopoulou M, et al. EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures. Blood 2009; 114:1707-1716.
32. Yamashita T, Ohneda K, Nagano M, et al. Hypoxia-inducible transcription factor-2alpha in endothelial cells regulates tumor neovascularization through activation of ephrin A1. J Biol Chem 2008; 283:18926-18936.
33. Larrivee B, Freitas C, Suchting S, et al. Guidance of vascular development: lessons from the nervous system. Circ Res 2009; 104:428-441.
34. Jakobsson L, Domogatskaya A, Tryggvason K, et al. Laminin deposition is dispensable for vasculogenesis but regulates blood vessel diameter independent of flow. FASEB J 2008; 22:1530-1539.
35. Stratman AN, Malotte KM, Mahan RD, et al. Pericyte recruitment during vasculogenic tube assembly stimulates endothelial basement membrane matrix formation. Blood 2009; 114:5091-5101.
36. Thyboll J, Kortesmaa J, Cao R, et al. Deletion of the laminin alpha4 chain leads to impaired microvessel maturation. Mol Cell Biol 2002; 22:1194-1202.
37. Fukai N, Eklund L, Marneros AG, et al. Lack of collagen XVIII/endostatin results in eye abnormalities. EMBO J 2002; 21:1535-1544.
38. Qian RG, Glanville RW. Separation and characterization of two polypeptide chains from the 7S cross-linking domain of basement-membrane (type IV) collagen. Biochem J 1984; 222:447-452.
39. Bailey AJ, Sims TJ, Light N. Cross-linking in type IV collagen. Biochem J 1984; 218:713-723.
40. Poschl E, Schlotzer-Schrehardt U, Brachvogel B, et al. Collagen IV is essential for basement membrane stability but dispensable for initiation of its assembly during early development. Development 2004; 131:1619-1628.
41. Gould DB, Phalan FC, Breedveld GJ, et al. Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly. Science 2005; 308:1167-1171.
42. Gould DB, Phalan FC, van Mil SE, et al. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med 2006; 354:1489-1496.
43. Plaisier E, Gribouval O, Alamowitch S, et al. COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps. N Engl J Med 2007; 357:2687-2695.
44. Holster T, Pakkanen O, Soininen R, et al. Loss of assembly of the main basement membrane collagen, type IV, but not fibril-forming collagens and embryonic death in collagen prolyl 4-hydroxylase I null mice. J Biol Chem 2007; 282:2512-2519.
45. Ruotsalainen H, Sipila L, Vapola M, et al. Glycosylation catalyzed by lysyl hydroxylase 3 is essential for basement membranes. J Cell Sci 2006; 119 (Pt 4):625-635.
46. Rautavuoma K, Takaluoma K, Sormunen R, et al. Premature aggregation of type IV collagen and early lethality in lysyl hydroxylase 3 null mice. Proc Natl Acad Sci USA 2004; 101:14120-14125.
47. Sipila L, Ruotsalainen H, Sormunen R, et al. Secretion and assembly of type IV and VI collagens depend on glycosylation of hydroxylysines. J Biol Chem 2007; 282:33381-33388.
48. Maki JM, Rasanen J,Tikkanen H, et al. Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. Circulation 2002; 106:2503-2509.
49. Hornstra IK, Birge S, Starcher B, et al. Lysyl oxidase is required for vascular and diaphragmatic development in mice. J Biol Chem 2003; 278:14387-14393.
50. Liu X, Zhao Y, Gao J, et al. Elastic fiber homeostasis requires lysyl oxidase-like 1 protein. Nat Genet 2004; 36:178-182.
51. Myllyharju J, Kivirikko KI. Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet 2004; 20:33-43.
52. Takaluoma K, Hyry M, Lantto J, et al. Tissue-specific changes in the hydroxylysine content and cross-links of collagens and alterations in fibril morphology in lysyl hydroxylase 1 knock-out mice. J Biol Chem 2007; 282:6588-6596.
53. Akagawa H, Narita A, Yamada H, et al. Systematic screening of lysyl oxidase-like (LOXL) family genes demonstrates that LOXL2 is a susceptibility gene to intracranial aneurysms. Hum Genet 2007; 121:377-387.
54. Jones RA, Kotsakis P, Johnson TS, et al. Matrix changes induced by transglutaminase 2 lead to inhibition of angiogenesis and tumor growth. Cell Death Differ 2006; 13:1442-1453.
55. Tan K, Lawler J. The interaction of thrombospondins with extracellular matrix proteins. J Cell Commun Signal J Cell Commun Signal 2009; 3(3/4):177-187.
56. Margosio B, Rusnati M, Bonezzi K, et al. Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. Int J Biochem Cell Biol 2008; 40:700-709.
57. GreenawayJ, Lawler J, Moorehead R, et al. Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol 2007; 210:807-818.
58. Zhang X, Kazerounian S, Duquette M, et al. Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J 2009; 23:3368-3376.
59. Crawford SE, Stellmach V, Murphy-Ullrich JE, et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998; 93:1159-1170.
60. Iruela-Arispe ML, Luque A, Lee N. Thrombospondin modules and angiogenesis. Int J Biochem Cell Biol 2004; 36:1070-1078.
61. Krady MM, Zeng J, Yu J, et al. Thrombospondin-2 modulates extracellular matrix remodeling during physiological angiogenesis. Am J Pathol 2008; 173:879-891.
62. Brechot N, Gomez E, Bignon M, et al. Modulation of macrophage activation state protects tissue from necrosis during critical limb ischemia in thrombo-spondin-1-deficient mice. PLoS ONE 2008; 3:e3950.
63. Sun J, Hopkins BD, Tsujikawa K, et al. Thrombospondin-1 modulates VEGF-A-mediated Akt signaling and capillary survival in the developing retina. Am J Physiol Heart Circ Physiol 2009; 296:H1344-H1351.
64. Isenberg JS, Martin-Manso G, Maxhimer JB, Roberts DD. Regulation of nitricoxide signalling by thrombospondin 1: implications for antiangiogenic therapies. Nat Rev Cancer 2009; 9:182-194.
65. Le Jan S, Amy C, Cazes A, et al. Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol 2003; 162:1521-1528.
66. Chomel C, Cazes A, Faye C, et al. Interaction of the coiled-coil domain with glycosaminoglycans protects angiopoietin-like 4 from proteolysis and regulates its antiangiogenic activity. FASEB J 2009; 23:940-949.
67. Cazes A, Galaup A, Chomel C, et al. Extracellular matrix-bound angiopoietin-like 4 inhibits endothelial cell adhesion, migration, and sprouting and alters actin cytoskeleton. Circ Res 2006; 99:1207-1215.
68. Galaup A, Cazes A, Le Jan S, et al. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci USA 2006; 103:18721-18726.
69. Sainson RC, Aoto J, Nakatsu MN, et al. Cell-autonomous notch signaling regulates endothelial cell branching and proliferation during vascular tubulo-genesis. FASEB J 2005; 19:1027-1029.
70. Nikolova G, Strilic B, Lammert E. The vascular niche and its basement membrane. Trends Cell Biol 2007; 17:19-25.
71. Abramsson A, Kurup S, Busse M, et al. Defective N-sulfation of heparan sulfate proteoglycans limits PDGF-BB binding and pericyte recruitment in vascular development. Genes Dev 2007; 21:316-331.
72. Stenzel D, Nye E, Nisancioglu M, et al. Peripheral mural cell recruitment requires cell-autonomous heparan sulfate. Blood 2009; 114:915-924.
73. Greenberg JI, Shields DJ, Barillas SG, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008; 456:809-813.
74. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005; 97:512-523.
75. Risinger GM Jr, Updike DL, Bullen EC, et al. TGF-beta suppresses the upregulation of MMP-2 by vascular smooth muscle cells in response to PDGF-BB. Am J Physiol Cell Physiol 2010; 298:C191-C201.
76. Chaudhry SS, Cain SA, Morgan A, et al. Fibrillin-1 regulates the bioavailability of TGFbeta1. J Cell Biol 2007; 176:355-367.
77. Chen Q, Sivakumar P, Barley C, et al. Potential role for heparan sulfate proteoglycans in regulation of transforming growth factor-beta (TGF-beta) by modulating assembly of latent TGF-beta-binding protein-1 J Biol Chem 2007; 282:26418-26430.
78. Wipff PJ, Rifkin DB, Meister JJ, Hinz B. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol 2007; 179:1311-1323.
79. Wells RG, Discher DE. Matrix elasticity, cytoskeletal tension, and TGF-beta: the insoluble and soluble meet. Sci Signal 2008; 1:e13.
80. Akimov SS, Belkin AM. Cell-surface transglutaminase promotes fibronectin assembly via interaction with the gelatin-binding domain of fibronectin: a role inTGFbeta-dependent matrix deposition. J Cell Sci 2001; 114 (Pt 16):2989-3000.
81. Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. Cell 2006; 126:677-689.
82. Levental KR, Yu H, Kass L, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009; 139:891-906.